MedPath
EMA Product

Pregabalin Accord

Product approved by European Medicines Agency (EU)

Basic Information

Pregabalin Accord

Regulatory Information

EMEA/H/C/004024

Authorised

August 28, 2015

June 25, 2015

19

January 27, 2025

Company Information

Spain

Edificio Este Planta 6a World Trade Center Moll De Barcelona S/n 08039 Barcelona

ACCORD HEALTHCARE SL

Drug Classification

Generic Medicine

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication Epilepsy - Pregabalin Accord is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Generalised Anxiety Disorder - Pregabalin Accord is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

Overview Summary

This is a summary of the European public assessment report (EPAR) for Pregabalin Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pregabalin Accord. For practical information about using Pregabalin Accord, patients should read the package leaflet or contact their doctor or pharmacist.

© Copyright 2025. All Rights Reserved by MedPath